A History of Outperforming Analyst Forecasts and Beating the Odds: Akebia Therapeutics Inc. (AKBA)

With 1.33 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.84 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.6700 whereas the lowest price it dropped to was $1.6200. The 52-week range on AKBA shows that it touched its highest point at $1.84 and its lowest point at $0.49 during that stretch. It currently has a 1-year price target of $4.33. Beta for the stock currently stands at 0.80.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AKBA was down-trending over the past week, with a drop of -0.61%, but this was up by 3.80% over a month. Three-month performance surged to 70.83% while six-month performance rose 11.56%. The stock gained 42.61% in the past year, while it has gained 32.26% so far this year. A look at the trailing 12-month EPS for AKBA yields -0.33 with Next year EPS estimates of -0.27. For the next quarter, that number is -0.04. This implies an EPS growth rate of 39.71% for this year and 11.11% for next year.


Float and Shares Shorts:

At present, 184.14 million AKBA shares are outstanding with a float of 165.56 million shares on hand for trading. On Jan 31, 2024, short shares totaled 8.78 million, which was 4.66% higher than short shares on Dec 29, 2023. In addition to Mr. John P. Butler MBA as the firm’s CEO, President & Director, Mr. Michel Dahan serves as its Senior VP & COO.

Institutional Ownership:

Through their ownership of 26.97% of AKBA’s outstanding shares, institutional investors have minority control over the company.


Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AKBA since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With AKBA analysts setting a high price target of $5.00 and a low target of $4.00, the average target price over the next 12 months is $4.33. Based on these targets, AKBA could surge 204.88% to reach the target high and rise by 143.9% to reach the target low. Reaching the average price target will result in a growth of 164.02% from current levels.

Summary of Insider Activity:

Insiders traded AKBA stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 12 while that of sell transactions has risen to 23 over the past year. The total number of shares bought during that period was 1,280,000 while 502,922 shares were sold.